Novartis AG
No trades
No trades
Price target
135.820.000.00%
The 24 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 31 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of NOT is 129.32 EUR — it has increased by 1.57% in the past 24 hours. Watch Novartis AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Novartis AG stocks are traded under the ticker NOT.
NOT stock has risen by 5.36% compared to the previous week, the month change is a −2.68% fall, over the last year Novartis AG has showed a 23.16% increase.
We've gathered analysts' opinions on Novartis AG future price: according to them, NOT price has a max estimate of 162.86 EUR and a min estimate of 106.29 EUR. Watch NOT chart and read a more detailed Novartis AG stock forecast: see what analysts think of Novartis AG and suggest that you do with its stocks.
NOT stock is 1.21% volatile and has beta coefficient of 0.56. Track Novartis AG stock price on the chart and check out the list of the most volatile stocks — is Novartis AG there?
Today Novartis AG has the market capitalization of 231.75 B, it has increased by 0.99% over the last week.
Yes, you can track Novartis AG financials in yearly and quarterly reports right on TradingView.
Novartis AG is going to release the next earnings report on Oct 27, 2026. Keep track of upcoming events with our Earnings Calendar.
NOT earnings for the last quarter are 2.11 EUR per share, whereas the estimation was 1.90 EUR resulting in a 11.17% surprise. The estimated earnings for the next quarter are 1.98 EUR per share. See more details about Novartis AG earnings.
Novartis AG revenue for the last quarter amounts to 12.62 B EUR, despite the estimated figure of 12.33 B EUR. In the next quarter, revenue is expected to reach 12.84 B EUR.
NOT net income for the last quarter is 2.79 B EUR, while the quarter before that showed 2.68 B EUR of net income which accounts for 0.00% change. Track more Novartis AG financial stats to get the full picture.
Yes, NOT dividends are paid annually. The last dividend per share was 4.09 EUR. As of today, Dividend Yield (TTM)% is 3.09%. Tracking Novartis AG dividends might help you take more informed decisions.
Novartis AG dividend yield was 3.38% in 2025, and payout ratio reached 61.77%. The year before the numbers were 3.95% and 67.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 29, 2026, the company has 75.27 K employees. See our rating of the largest employees — is Novartis AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novartis AG EBITDA is 18.39 B EUR, and current EBITDA margin is 40.92%. See more stats in Novartis AG financial statements.
Like other stocks, NOT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novartis AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novartis AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novartis AG stock shows the buy signal. See more of Novartis AG technicals for a more comprehensive analysis.